Retroperitoneal liposarcomas: the experience of a tertiary Asian center

Abstract

BackgroundLiposarcoma is the single most common soft tissue sarcoma in the retroperitoneum.Materials and methodsA retrospective review of patients with primary retroperitoneal liposarcoma treated between June 1990 and June 2005 were conducted to evaluate the clinical results of resection for retroperitoneal liposarcomas (RPLS) and the prognostic factors for disease recurrence and patient survival in an Asian population.ResultsTwenty-one patients operated on for curative intent (12 Males, 9 Females; mean age: 52.4 years) were evaluated. Of these, 13 presented with tumors that were well differentiated (61.9%), 4 (19.0%) with myxoid/round cell, 3 (14.3%) with dedifferentiated and 1(4.8%) with pleomorphic morphology. The median tumor burden was 36 cm (9-83). Median follow-up time was 62 months. There was no peri-operative mortality and morbidity occurred in 6(28.6%) patients. Surgical margins were involved in 10(47.6%) patients. Resection of contiguous organs was required in 15(71.4%) to achieve gross surgical margins. Eleven out of the 21(52%) of the patients had recurrence of the tumor. Median disease-free survival was 19 months and the overall 3- and 5-year survival rate was 87% and 49% respectively.ConclusionAn aggressive surgical approach in both primary and recurrent RPLS in our institution is associated with 3- and 5-year survival rate of 87% and 49% respectively. Contiguous organ resection is often required to achieve local control.

Soft-tissue Sarcomas in the Asia-Pacific Region: A Systematic Review

“…One factor is the range of sarcoma histotypes, sites, grades, and stages of disease assessed, which all influence patient prognosis. In this review, for example, the 5-year OS rate was about 50% for retroperitoneal liposarcoma (33% FNCLCC grade 3) (Lee et al, 2011), whereas the 53-month OS rate was 93% for extremity liposarcoma (11% high grade) (Ng and Tan, 2009). The quality of surgery also plays a key role in survival outcomes (Stojadinovic et al, 2002;Gronchi et al, 2005) and may have differed across, and possibly within, the centres of the included studies.…”

“…Only 13 studies specified whether STS was primary or recurrent [8 primary (Dickinson et al, 2006;Hui et al, 2006;Wu et al, 2006;An et al, 2007;Kim et al, 2008a;Ng and Tan, 2009;Wang et al, 2009;Liu et al, 2010); 5 primary or recurrent (Hsieh et al, 2003;Kiatisevi et al, 2006;Moncrieff et al, 2008;Miki et al, 2010;Cho et al, 2011)]. Patients had local disease in 15 studies (Choong et al, 2003;Campbell et al, 2004;Hsu et al, 2004;Dickinson et al, 2006;Hui et al, 2006;An et al, 2007;Kim et al, 2007;2008c;Pervaiz et al, 2008;Rudiger et al, 2009;Wang et al, 2009;Liu et al, 2010;Cho et al, 2011;Han et al, 2011), and local or metastatic disease in 7 studies (Wu et al, 2006;Chan et al, 2008;Moncrieff et al, 2008;Koh et al, 2009;Jun et al, 2010;Park et al, 2010;Lee et al, 2011). The remaining 10 studies did not specify whether disease was local or metastatic.…”

“…In 1 study, 11 (31%) patients had amputations (Chan et al, 2008). Postoperative morbidity was reported for 6 (29%) patients in 1 study of retroperitoneal liposarcoma (Lee et al, 2011). No patients had preoperative radiotherapy or chemotherapy.…”

“…Overall survival (5-year rates; 2 studies) was lower for extremity and trunk pleomorphic sarcoma (30%; grade not reported) (Chan et al, 2008) than retroperitoneal liposarcoma (49%; 33% FNCLCC grade 3) (Lee et al, 2011). The rate of local recurrence and/or distant metastases (4 studies) varied from 33% for extremity and trunk pleomorphic sarcoma (grade not reported) (Chan et al, 2008) to 52% for retroperitoneal liposarcoma (33% FNCLCC grade 3) (Lee et al, 2011). Adverse events were reported in only 1 study (postoperative morbidity).…”

Case Report: Myxoid Liposarcoma in Retroperitoneum

“…With population aging, the incidence is expected to keep rising. Among the most common are prostate, lung and colon/rectum in man; and breast, lung and colon/rectum in women [8]. This case report is a rare neoplasm, usually more common in specialized medical centers, which do not appear routinely, like the others previously mentioned.…”